Clinical Trials Logo

Corneal Disease clinical trials

View clinical trials related to Corneal Disease.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05700864 Withdrawn - Neuropathy Clinical Trials

NGF Treatment for Patients With Neuropathic Corneal Pain

Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28 subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP, corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of study (16 weeks post treatment).

NCT ID: NCT03421548 Withdrawn - Glaucoma Clinical Trials

Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1

BKPro
Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and performance of the EYEMATE system in patients undergoing concomitant implantation of a BKPro type 1 and an EYEMATE sensor over the 24 months period beginning at implantation.

NCT ID: NCT02374723 Withdrawn - Corneal Disease Clinical Trials

Evaluation of Biosynthetic Constructs to Replace Donor Corneas

Start date: June 2015
Phase: Phase 1
Study type: Interventional

Constructs made from cross-linked Human Recombinant Collagen type III are being used instead of human donor corneas in 6 patients at Deep anterior lamellar cornea grafting. Six patients serve as controls and are receiving human donor corneas using the same surgical technique. The twelve patients will be recruited from the local waiting list for patients to be undergoing corneal grafting. If the patients meet the inclusion criteria and agree to participate following oral and written consent, they will be randomized to either group. The patients will be followed for 12 months and documented with OCT, In Vivo Confocal Microscopy, slit lamp photography a o. The study is planned as a safety study with initial efficacy documentation.